| 
			
			 Researchers examined data on 466,677 people who had plastic and 
			reconstructive procedures for the nose, eye, breast, abdomen or soft 
			tissue from 2007 to 2015. Almost 55 percent of patients received 
			painkiller prescriptions afterwards, and 92 percent of the 
			prescriptions filled were for opioids. 
 Patients who filled an opioid prescription shortly before or after 
			surgery were about three times as likely as those who didn't to 
			still be using opioids up to six months or even a year later, the 
			study found.
 
 "On the one hand, we do not want our patients to suffer in the 
			postoperative period - we want to treat their pain," said senior 
			study author Dr. Sam Most, chief of the division of facial plastic 
			and reconstructive surgery at Stanford University School of Medicine 
			in California.
 
			
			 
			
 "At the same time, we do not want to cause further problems, such as 
			prolonged use or even addiction," Most said by email. "This is our 
			quandary."
 
 None of the patients had filled prescriptions for opioids in the 
			year before surgery.
 
 Patients commonly need pain relief in the days or weeks after 
			surgery. The researchers defined "persistent" opioid use as filling 
			prescriptions for these narcotics between 90 and 180 days after 
			surgery. More than 30,000 patients, or almost 7 percent, became 
			persistent opioid users after surgery.
 
 And more than 10,000 patients, or 2.3 percent, remained on these 
			drugs even longer, still using opioids up to one year after surgery.
 
 Many patients who filled opioid prescriptions after surgery had 
			other ongoing health problems, researchers report in JAMA Facial 
			Plastic Surgery. About 39 percent suffered from chronic pain, while 
			14 percent had existing substance abuse issues and 6 percent had 
			anxiety.
 
 Opioid prescriptions were most common after nose jobs, when they 
			were prescribed 66 percent of the time.
 
 And 61 percent of women who had breast reconstruction or enhancement 
			surgery were prescribed opioids.
 
			
            [to top of second column] | 
             
			Prescription rates for opioids after nose and breast procedures have 
			been rising in recent years, the study found, even as rates fell or 
			held stable for other types of plastic surgery. 
			A limitation of the study is that researchers only had data on 
			prescriptions filled, not how much medication patients actually took 
			or whether they obtained additional opioids from friends, family or 
			other sources. They also lacked data to determine whether or not the 
			prescriptions were necessary or appropriate.
 Even so, the findings add to evidence suggesting that prolonged 
			opioid use after surgery might not be due to pain, the authors 
			conclude. In some instances, alternative painkillers like 
			acetaminophen (Tylenol) or non-steroidal anti-inflammatory drugs (NSAIDs) 
			such as ibruprofen (Motrin) might be effective for managing pain 
			after surgery, Most said.
 
 "Opioids certainly have a role for severe post-operative pain, but 
			our use of opioids in the U.S. has gone well beyond the need since 
			the mid 1990's," said Dr. Chad Brummett, co-director of the Michigan 
			Opioid Prescribing Engagement Network, and an anesthesiology 
			professor at the University of Michigan Medical School in Ann Arbor.
 
 
			 
			"There are many surgeries for which opioids are not necessary but 
			for which they are regularly prescribed," Brummett, who wasn't 
			involved in the study, said by email. "We have undervalued simple, 
			but effective medications, such as acetaminophen and non-steroidal 
			anti-inflammatory medications (e.g. ibuprofen), which can be taken 
			for a few days by the vast majority of patients without concern."
 
 SOURCE: https://bit.ly/2Y9ubrW JAMA Facial Plastic Surgery, online 
			March 7, 2019.
 
			[© 2019 Thomson Reuters. All rights 
				reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. |